|Day Low/High||45.31 / 47.71|
|52 Wk Low/High||18.93 / 59.25|
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
Expert says weed-related products for pets could become a $55 billion-a-year business.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
A look at CGC's charts and our latest strategy.
'There's too much hype too soon,' Canopy Growth chief Bruce Linton says.
Covered calls may be the best bet -- or wait for a dip.
Canadian marijuana legalization and U.S. approval of industrial hemp are coming.
Cannabis companies should be taking advantage of the mania to raise money.
Don't try to explain the stock's meteoric rise on a fundamental or technical basis, because it defies both.
This options trade combines some upside with a chance to buy TLRY at a decent price.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
You don't want your money to go up in smoke.
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.
Hexo is pursuing joint ventures in cosmetics, health care, candy, edibles, and vape companies.
The underlying action, particularly the weakness in the technology sector, is reason for concern.
Analysts and advisors stand by Nike as NFL.
Several cannabis companies are planning to go public this fall.
Tilray reported a 95% jump in second-quarter revenue to $9.7 million, ahead of the Wall Street estimate of $9 million, in its first earnings release since it went public on July 19.
This is simply a short-term thesis that the cannabis rally will cool this week.
Seasonality hasn't mattered in a number or years so why should light volume new highs be an issue?
The Nasdaq-listed provider of medical marijuana will compete with other firms as Canada opens itself to general adult use of marijuana this fall.